Skip to main content
Program
#AHA25
Late-Breaking Science
Daily Coverage
Industry Highlights
Photo Gallery
Journeys
Late-Breaking Science
Celebrating a century of cardiovascular science
Intensive blood pressure control, tirzepatide and novel gene editing therapy.
Advances in lipid therapeutics
New approaches to managing AFib
Medical therapy for heart failure
Innovation in prevention
Save the date for #AHA25 in New Orleans
Harnessing AI for better heart health
Improving guideline-directed medical therapy, comparing wearable versus implanted sensors, boosting echocardiogram performance and automating echocardiographic interpretation.
Sponsored
Unmet Needs in Hypertension Toolkit
Learn more about initial management of HTN, diagnosing resistant hypertension, sharing decision-making with your patient and more.
Coronary and valvular heart disease
Liberal or restrictive oxygenation, GLP-1 agonist therapy, edoxaban and spironolactone.
Redefining arrhythmia treatment
Catheter ablation, OPTION and Brain-AF.
Clinical Guideline Sessions
Get up to speed on all of the updates in guidelines.
Late-Breaking Science for Sunday
Two presentations feature results from intervention and prevention studies.
Featured Science for Saturday
Check out these featured studies.
Don't miss today's Main Events
Six powerful Main Events to kick off your Scientific Sessions 2024.
#AHA24 Late-Breaking and Featured Science announced
See the impressive lineup of science planned for presentation at Scientific Sessions 2024.
Late-breaking science| Achieving equity in prevention
Health care worker-led trial improves hypertension control, automated pharmacy referral for statin prescribing, SBP levels improving CVD outcomes and reducing hypertension in low-income population.
Novel mechanisms for lipid-lowering therapy
Late-breaking science: AI at the bedside
Shocking decisions in AFib care
Drugs, diet and delivery can optimize hypertension outcomes
Heart failure late-breaking science
Weight-loss drug reduced secondary CV risk in people with overweight or obesity without diabetes
Trials’ results suggest new approaches to reducing CVD risk and symptoms
Late-Breaking Science announced
Early ablation bests medication in treatment naïve AFib patients
First-in-class aminopeptidase-A inhibitor fails to reduce treatment-resistant hypertension
Trial results shed light on tool for assessing VTE risk, routine anticoagulation for non-hospitalized COVID patients, and clinical outcomes of open vs. endovascular surgery for advanced PAD
